Primidone

證據等級: L5

預測適應症: 10 個

Primidone: From Epilepsy/Essential Tremor to Reflex Epilepsy Syndromes (Audiogenic Seizures)

One-Sentence Summary

Primidone is a barbiturate-derived anticonvulsant, established for epilepsy and essential tremor. TxGNN generated ten candidate new indications for this drug, all clustered around reflex/stimulus-triggered seizure syndromes and two unrelated outliers; the model’s single top-ranked hit (trigeminal nerve neoplasm) is almost certainly a name-collision artefact rather than a genuine signal. The most defensible candidate is audiogenic (sound-triggered) seizures, supported only by decades-old preclinical/animal pharmacology — zero clinical trials exist for any of the ten candidates.

Quick Overview

Item	Content
Original Indication	Epilepsy (tonic-clonic/partial seizures) and essential tremor — formal indication text unavailable; Primidone is not currently registered in Australia
Predicted New Indication	Audiogenic seizures (a reflex epilepsy subtype); trigeminal neuralgia and startle epilepsy are secondary candidates in the same cluster
TxGNN Prediction Score	99.99% (audiogenic seizures, model rank 471 of output)
Evidence Level	L3
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Note on the model’s top hit: TxGNN’s #1-ranked prediction for this drug was trigeminal nerve neoplasm (score 99.99%, rank 189). The evidence pack’s own mechanistic review flags this as a very likely false positive — Primidone has an anticonvulsant/GABAergic mechanism with no known link to tumour biology, and the prediction has zero supporting trials or literature. It most likely reflects the knowledge-graph embedding confusing “trigeminal nerve neoplasm” with the unrelated term “trigeminal neuralgia.” This report focuses instead on the candidates with genuine mechanistic and literature support.

Why is This Prediction Reasonable?

Primidone is a barbiturate derivative metabolised to phenobarbital and phenylethylmalonamide (PEMA). Its mechanism combines GABA-A receptor potentiation with voltage-gated sodium-channel blockade — a broad-spectrum anticonvulsant/anti-tremor profile that has kept it in use for generalised and partial epilepsy and for essential tremor.

Reflex epilepsies (audiogenic, startle, reading, thinking, micturition-induced, and orgasm-induced seizures) are seizure subtypes triggered by specific sensory or cognitive stimuli rather than distinct diseases with separate pathophysiology. Because broad-spectrum GABAergic/sodium-channel-blocking anticonvulsants are mechanistically applicable across seizure types, it is biologically plausible — though not clinically proven — that Primidone could be effective in these stimulus-triggered subtypes, similar to how it is already used off-label in cortical/stimulus-sensitive myoclonus.

The strongest direct evidence is a 1964 animal study that tested pyramidone (a primidone-related compound) against audiogenic convulsions, and a 1976 mouse study examining primidone’s effect on brain enzyme activity in audiogenic epilepsy. Both are direct pharmacological tests in a relevant disease model, but both are more than 45 years old, small in scale, and pre-date modern trial standards. No human clinical evidence exists for any of the reflex epilepsy candidates.

Clinical Trial Evidence

Currently no related clinical trials registered — for any of the ten TxGNN-predicted indications for Primidone (query log confirms 0 ClinicalTrials.gov and 0 ICTRP results across all ten disease queries).

Literature Evidence

PMID	Year	Type	Journal	Target Indication	Key Findings
3925335	1985	RCT (general epilepsy)	New England Journal of Medicine	General/micturition-induced seizures	10-centre RCT (n=622) comparing carbamazepine, phenobarbital, phenytoin, and primidone in partial/secondary generalised tonic-clonic seizures; establishes primidone’s general anticonvulsant efficacy but not specific to any reflex subtype
14249886	1964	Animal Study	Biulleten’ eksperimental’noi biologii i meditsiny	Audiogenic seizures	Direct preclinical test of pyramidone (primidone-related compound) against audiogenic convulsions in animals
184518	1976	Animal Study	Neurologie et psychiatrie	Audiogenic seizures	Effect of phenobarbital, diphenylhydantoin and primidone on brain enzyme activity in mice with audiogenic epilepsy
8548670	1995	Case Report	Chinese Medical Journal (Free China ed)	Startle epilepsy	Case of startle epilepsy presenting as atonic drop attacks; describes clinical phenotype, not primidone-specific treatment data
8891399	1995	Review	Clinical Neuroscience	Audiogenic/reading seizures (stimulus-sensitive myoclonus)	Reviews primidone (500–1000 mg/day) among agents used for cortical/stimulus-sensitive myoclonus
15246950	2004	Review	Epileptic Disorders	Trigeminal neuralgia	Reviews antiepileptic drug use outside epilepsy; evidence for such uses generally limited to case series/small trials
9068876	1996	Review	Bailliere’s Clinical Neurology	Micturition-induced seizures	Lists primidone among established antiepileptic drugs for partial and generalised seizures
11096777	2000	Review	Current Treatment Options in Neurology	Micturition-induced seizures	Primidone/phenobarbital noted as later-line options in primary generalised epilepsies
19054416	2009	Cohort	Epilepsia	Thinking seizures	Studies race/setting effects on initial AED choice in newly diagnosed geriatric epilepsy; general epidemiology, not disease-specific
3092407	1986	Review	Therapeutic Drug Monitoring	Trigeminal neuralgia	Discusses carbamazepine-primidone pharmacokinetic interactions in the context of trigeminal neuralgia treatment

Australia Market Information

Primidone has no ARTG entries and is not currently marketed in Australia (0 licences on file).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No warnings, contraindications, or drug-interaction data were available in this evidence pack (DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: No clinical trials exist for any of the ten TxGNN-predicted indications, the best-supported candidate (audiogenic seizures) rests on animal pharmacology from the 1960s–70s, and Primidone is not currently marketed in Australia. The model’s own top-ranked hit (trigeminal nerve neoplasm) is very likely a false positive, underscoring the need for mechanistic screening before acting on TxGNN rank alone.

To proceed, the following is needed:

TGA-approved Product Information / PI warnings and contraindications (currently a blocking data gap)
Confirmed mechanism-of-action data from DrugBank (currently a data gap)
A targeted literature search specifically on primidone in reflex/stimulus-triggered epilepsy syndromes, to update the 1960s–70s preclinical evidence base
Consideration of whether audiogenic/startle/reading seizure phenotypes warrant a pilot case series before any trial planning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.